Silence Therapeutics Extended Base Flags 300p Plus Return

SLN Silence Therapeutics Technical Analysis 220115

By definition, the name of the game in charting is ideally to be able to identify a well-defined patterns which have been in place over a long period and therefore are backed by probability to be all the more reliable.

The present daily chart configuration of Silence Therapeutics PLC (LSE:SLN) looks to have just such a pattern in the form of an extended base/U-shaped reversal which has been in place since last year’s March/April peaks towards the 400p level. Indeed, it was always expected that there would be some kind of consolidation after a very strong run which saw the shares double from the beginning of December 2013 to the end of the first quarter of last year.

The current bullish configuration is backed by two additional key features. The first is October’s brief bear trap probe towards £1.50 and then the subsequent higher lows the shares have put in place over recent months.

The second is the way that in January we have seen a break above the still falling 200 day moving average, something which if sustained would be as powerful signal as the overall post April price pattern. The best way forward currently is probably to regard the shares as being in a rising trend channel from May with the floor of the channel currently running at the 50 day moving average level £2.11.

While this notional double support zone remains in place on a weekly close basis we can look towards the top of the 2014 channel at 300p plus over the next 1 to 2 months, something which offers a reasonable risk reward technical trade.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    DirectorsTalk

    More articles like this

    Silence Therapeutics plc

    Silence Therapeutics analyst presentation 6th March

    Silence Therapeutics plc, (LON:SLN) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, will announce its Preliminary Results for the twelve months ended

    Silence Therapeutics plc

    A further European patent for Silence Therapeutics plc

    Silence Therapeutics plc, AIM:SLN a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced today that on 17 January 2018 the European Patent

    Silence Therapeutics plc

    Silence Therapeutics Notice of Interim Results

    Silence Therapeutics plc, LON:SLN (“Silence” or “the Company”) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, will announce results for the six